Phaseline

Targets › GCNT1

GCNT1 (Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Glycosyltransferase that catalyzes the transfer of an N-acetylglucosamine (GlcNAc) moiety in beta1-6 linkage from UDP-GlcNAc onto mucin-type core 1 O-glycan to form the branched mucin-type core 2 O-glycan. The catalysis is metal ion-independent and occurs with inversion of the anomeric configuration of sugar donor (By similarity). (UniProt, Q02742)

Open in Phaseline: the race on GCNT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Margaret Gatti-MaysNaxitamab
Humanized anti-GD2 monoclonal antibody
GCNT1Phase 1Anatomic Stage IV Breast Cancer AJCC v8Oct 2027

Conditions

Anatomic Stage IV Breast Cancer AJCC v8 (1)

Modalities

mixed (1)

Companies

Margaret Gatti-Mays (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.